524 related articles for article (PubMed ID: 17555404)
41. Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis.
Almudéver P; Milara J; De Diego A; Serrano-Mollar A; Xaubet A; Perez-Vizcaino F; Cogolludo A; Cortijo J
Thorax; 2013 Oct; 68(10):938-48. PubMed ID: 23739137
[TBL] [Abstract][Full Text] [Related]
42. Tetrahydrobiopterin is a secretory product of murine vascular endothelial cells.
Walter R; Schaffner A; Blau N; Kierat L; Schoedon G
Biochem Biophys Res Commun; 1994 Sep; 203(3):1522-6. PubMed ID: 7945301
[TBL] [Abstract][Full Text] [Related]
43. Novel therapies targeting vascular endothelium.
Tousoulis D; Antoniades C; Koumallos N; Marinou K; Stefanadi E; Latsios G; Stefanadis C
Endothelium; 2006; 13(6):411-21. PubMed ID: 17169773
[TBL] [Abstract][Full Text] [Related]
44. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice.
Hattori Y; Hattori S; Wang X; Satoh H; Nakanishi N; Kasai K
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):865-70. PubMed ID: 17272747
[TBL] [Abstract][Full Text] [Related]
45. Insulin resistance and endothelial cell dysfunction: studies in mammalian models.
Kearney MT; Duncan ER; Kahn M; Wheatcroft SB
Exp Physiol; 2008 Jan; 93(1):158-63. PubMed ID: 17933859
[TBL] [Abstract][Full Text] [Related]
46. Folic Acid Promotes Recycling of Tetrahydrobiopterin and Protects Against Hypoxia-Induced Pulmonary Hypertension by Recoupling Endothelial Nitric Oxide Synthase.
Chalupsky K; Kračun D; Kanchev I; Bertram K; Görlach A
Antioxid Redox Signal; 2015 Nov; 23(14):1076-91. PubMed ID: 26414244
[TBL] [Abstract][Full Text] [Related]
47. The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endothelium.
Wunderlich C; Schober K; Schmeisser A; Heerwagen C; Tausche AK; Steinbronn N; Brandt A; Kasper M; Schwencke C; Braun-Dullaeus RC; Strasser RH
J Mol Cell Cardiol; 2008 May; 44(5):938-47. PubMed ID: 18417152
[TBL] [Abstract][Full Text] [Related]
48. GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function.
Antoniades C; Shirodaria C; Van Assche T; Cunnington C; Tegeder I; Lötsch J; Guzik TJ; Leeson P; Diesch J; Tousoulis D; Stefanadis C; Costigan M; Woolf CJ; Alp NJ; Channon KM
J Am Coll Cardiol; 2008 Jul; 52(2):158-65. PubMed ID: 18598896
[TBL] [Abstract][Full Text] [Related]
49. Endothelial dysfunction, endothelial nitric oxide bioavailability, tetrahydrobiopterin, and 5-methyltetrahydrofolate in cardiovascular disease. Where are we with therapy?
Yuyun MF; Ng LL; Ng GA
Microvasc Res; 2018 Sep; 119():7-12. PubMed ID: 29596860
[TBL] [Abstract][Full Text] [Related]
50. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities.
Kietadisorn R; Juni RP; Moens AL
Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E481-95. PubMed ID: 22167522
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension.
Li Q; Youn JY; Cai H
J Hypertens; 2015 Jun; 33(6):1128-36. PubMed ID: 25882860
[TBL] [Abstract][Full Text] [Related]
52. Tetrahydrobiopterin regulation of eNOS redox function.
Chen DD; Chen LY; Xie JB; Shu C; Yang T; Zhou S; Yuan H; Chen AF
Curr Pharm Des; 2014; 20(22):3554-62. PubMed ID: 24180387
[TBL] [Abstract][Full Text] [Related]
53. Prevention of renal injury and endothelial dysfunction by chronic L-arginine and antioxidant treatment.
Arellano-Mendoza MG; Vargas-Robles H; Del Valle-Mondragon L; Rios A; Escalante B
Ren Fail; 2011; 33(1):47-53. PubMed ID: 21219205
[TBL] [Abstract][Full Text] [Related]
54. Tetrahydrobiopterin is released from and causes preferential death of catecholaminergic cells by oxidative stress.
Choi HJ; Jang YJ; Kim HJ; Hwang O
Mol Pharmacol; 2000 Sep; 58(3):633-40. PubMed ID: 10953058
[TBL] [Abstract][Full Text] [Related]
55. Maintenance of cellular tetrahydrobiopterin homeostasis.
Kim HL; Park YS
BMB Rep; 2010 Sep; 43(9):584-92. PubMed ID: 20846489
[TBL] [Abstract][Full Text] [Related]
56. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function.
Milstien S; Katusic Z
Biochem Biophys Res Commun; 1999 Oct; 263(3):681-4. PubMed ID: 10512739
[TBL] [Abstract][Full Text] [Related]
57. Malfunction of vascular control in lifestyle-related diseases: endothelial nitric oxide (NO) synthase/NO system in atherosclerosis.
Kawashima S
J Pharmacol Sci; 2004 Dec; 96(4):411-9. PubMed ID: 15613778
[TBL] [Abstract][Full Text] [Related]
58. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?
Balakumar P; Chakkarwar VA; Krishan P; Singh M
Biomed Pharmacother; 2009 Mar; 63(3):171-9. PubMed ID: 18823739
[TBL] [Abstract][Full Text] [Related]
59. Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species.
Duncan ER; Walker SJ; Ezzat VA; Wheatcroft SB; Li JM; Shah AM; Kearney MT
Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1311-9. PubMed ID: 17711985
[TBL] [Abstract][Full Text] [Related]
60. Tetrahydrobiopterin in cardiovascular health and disease.
Bendall JK; Douglas G; McNeill E; Channon KM; Crabtree MJ
Antioxid Redox Signal; 2014 Jun; 20(18):3040-77. PubMed ID: 24294830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
